Sudden cardiac death (SCD) in young, otherwise healthy individuals is often due to ventricular tachyarrhythmias, resulting from a variety of diseases, traditionally grouped into the categories of channelopathies (including Brugada syndrome, long-QT syndrome, short-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia) and cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compaction, arrhythmogenic right ventricular cardiomyopathy, and restrictive cardiomyopathy).
An emerging concept is that channelopathies and cardiomyopathies may overlap, as patients harboring variants in genes associated with channelopathies may develop ‘cardiomyopathy phenotypes’, and patients with genetic cardiomyopathies often develop ‘arrhythmic phenotypes’ resembling channelopathies. Furthermore, similar therapeutic dilemmas regarding genetic testing, family members' investigations, sports participation, and device implantation may be present. Hence, the clinician treating these conditions needs to have clinically relevant data for providing optimal treatment.
In the last decade, there have been vast advancements in the field of congenital arrhythmogenic conditions, the pathogenesis of some previously “idiopathic” conditions have been clarified, the genetic causes of some discovered and genotype-phenotype relationship described. Advanced cardiovascular imaging techniques such as cardiac PET and MRI with more detailed methods of performing electrophysiological studies had aided in elucidating the diagnosis and prognosis of these conditions.
Omics approaches can be used in these conditions to understand disease severity, natural progression, prognosis, and overlap between seemingly distinct phenotypes. Moreover, omics approaches can impact the clinical management and treatment plan with positive consequences for affected patients. Omics - integrate genetics studies with additional high-throughput data designed to interrogate the transcriptome, epigenome, proteome, metabolome, etc. Furthermore, therapeutic advanced options such as cardiac tissue ablation and subcutaneous ICDs have provided more treatment options for patients with these conditions.
In this Research Topic, we strive to provide evidence-based data regarding the etiology, diagnosis, prognosis, and treatment of congenital arrhythmogenic conditions to aid the therapeutic process.
Specific themes we would like contributors to address:
1) Channelopathies (e.g. LQTS, SQTS, Brugada syndrome, CPVT).
2) Arrhythmogenic cardiomyopathies (e.g. ARVC, LVNC, HCM, DCM).
3) Diagnostic approaches for patients with congenital arrhythmias.
4) Genetic consideration in assessing patients with arrhythmogenic conditions.
5) Therapeutic consideration in patients with arrhythmias (Ablation, ICD implantation).
6) Epidemiology and population medicine regarding arrhythmogenic conditions.
Sudden cardiac death (SCD) in young, otherwise healthy individuals is often due to ventricular tachyarrhythmias, resulting from a variety of diseases, traditionally grouped into the categories of channelopathies (including Brugada syndrome, long-QT syndrome, short-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia) and cardiomyopathies (hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compaction, arrhythmogenic right ventricular cardiomyopathy, and restrictive cardiomyopathy).
An emerging concept is that channelopathies and cardiomyopathies may overlap, as patients harboring variants in genes associated with channelopathies may develop ‘cardiomyopathy phenotypes’, and patients with genetic cardiomyopathies often develop ‘arrhythmic phenotypes’ resembling channelopathies. Furthermore, similar therapeutic dilemmas regarding genetic testing, family members' investigations, sports participation, and device implantation may be present. Hence, the clinician treating these conditions needs to have clinically relevant data for providing optimal treatment.
In the last decade, there have been vast advancements in the field of congenital arrhythmogenic conditions, the pathogenesis of some previously “idiopathic” conditions have been clarified, the genetic causes of some discovered and genotype-phenotype relationship described. Advanced cardiovascular imaging techniques such as cardiac PET and MRI with more detailed methods of performing electrophysiological studies had aided in elucidating the diagnosis and prognosis of these conditions.
Omics approaches can be used in these conditions to understand disease severity, natural progression, prognosis, and overlap between seemingly distinct phenotypes. Moreover, omics approaches can impact the clinical management and treatment plan with positive consequences for affected patients. Omics - integrate genetics studies with additional high-throughput data designed to interrogate the transcriptome, epigenome, proteome, metabolome, etc. Furthermore, therapeutic advanced options such as cardiac tissue ablation and subcutaneous ICDs have provided more treatment options for patients with these conditions.
In this Research Topic, we strive to provide evidence-based data regarding the etiology, diagnosis, prognosis, and treatment of congenital arrhythmogenic conditions to aid the therapeutic process.
Specific themes we would like contributors to address:
1) Channelopathies (e.g. LQTS, SQTS, Brugada syndrome, CPVT).
2) Arrhythmogenic cardiomyopathies (e.g. ARVC, LVNC, HCM, DCM).
3) Diagnostic approaches for patients with congenital arrhythmias.
4) Genetic consideration in assessing patients with arrhythmogenic conditions.
5) Therapeutic consideration in patients with arrhythmias (Ablation, ICD implantation).
6) Epidemiology and population medicine regarding arrhythmogenic conditions.